ArticleExpert opinion on therapeutic targets2013
TLR3 agonists and proinflammatory antitumor activities.
Article in Expert opinion on therapeutic targets, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Unveiling the sensing potential of innate lymphoid cells.Communications biology · 2026Review
- Toll-like receptor 3: a double-edged sword.Biomarker research · 2025Review
- Necrotic Cells from Head and Neck Carcinomas Release Biomolecules That Are Activating Toll-like Receptor 3.International journal of molecular sciences · 2023Article
- Toll‑like receptor 3 ligands for breast cancer therapies (Review).Molecular and clinical oncology · 2023Review
- Stem Cells as Target for Prostate cancer Therapy: Opportunities and Challenges.Stem cell reviews and reports · 2022Review
- Article
- Trial watch: TLR3 agonists in cancer therapy.Oncoimmunology · 2020Review
- Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy.Journal of immunology research · 2020Review
- Selection of adjuvants for vaccines targeting specific pathogens.Expert review of vaccines · 2019Review
- Concomitant type I IFN and M-CSF signaling reprograms monocyte differentiation and drives pro-tumoral arginase production.EBioMedicine · 2019Article
- Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma.Carcinogenesis · 2016Article
- Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis.Oncoimmunology · 2015Article
- Trial watch: Dendritic cell-based anticancer therapy.Oncoimmunology · 2014Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.